These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 28434400)

  • 21. Making urothelial carcinomas less immune to immunotherapy.
    Ramos JD; Yu EY
    Urol Oncol; 2016 Dec; 34(12):534-537. PubMed ID: 27836245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma.
    Ottaviano M; De Placido S; Ascierto PA
    Virchows Arch; 2019 Apr; 474(4):421-432. PubMed ID: 30747264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy.
    Chang X; Lu X; Guo J; Teng GJ
    Cancer Treat Rev; 2019 Mar; 74():49-60. PubMed ID: 30831375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
    Maxwell R; Jackson CM; Lim M
    Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune checkpoint inhibitors in the management of malignancies in transplant recipients.
    Regalla DKR; Williams GR; Paluri RK
    Postgrad Med J; 2018 Dec; 94(1118):704-708. PubMed ID: 30425139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarkers for immune therapy in gastrointestinal cancers.
    Weinberg BA; Hameed R; Marshall JL
    Clin Adv Hematol Oncol; 2019 Feb; 17(2):109-119. PubMed ID: 30845114
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Not Available].
    Reverdy T; Gau M; Karabajakian A; Neidhardt EM; Fayette J
    Bull Cancer; 2018 Dec; 105 Suppl 1():S35-S42. PubMed ID: 30595197
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Current events in immunotherapy for upper aerodigestive tract cancer].
    Outh-Gauer S; Le Tourneau C; Broudin C; Scotte F; Roussel H; Hans S; Mandavit M; Tartour E; Badoual C
    Ann Pathol; 2017 Feb; 37(1):79-89. PubMed ID: 28111039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of immune checkpoint blockade for brain metastases.
    Harary M; Reardon DA; Iorgulescu JB
    CNS Oncol; 2019 Jun; 8(2):CNS33. PubMed ID: 30854898
    [No Abstract]   [Full Text] [Related]  

  • 30. Combination Immunotherapy Approaches for Pancreatic Cancer Treatment.
    Cheng X; Zhao G; Zhao Y
    Can J Gastroenterol Hepatol; 2018; 2018():6240467. PubMed ID: 29707526
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Checkpoint Inhibitors in the Treatment of Upper Gastrointestinal Tract Tumors].
    Obermannova R
    Klin Onkol; 2017; 30(Supplementum3):50-54. PubMed ID: 29239193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The "immune checkpoints", how does it work].
    Granier C; Soumelis V; Mandavit M; Gibault L; Belazzoug R; de Guillebon E; Badoual C; Tartour E; Roussel H
    Ann Pathol; 2017 Feb; 37(1):18-28. PubMed ID: 28160999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Tissue biomarkers of response to anti-PD-1 immunotherapies in melanoma].
    Adam J; Tomasic G; Robert C
    Ann Pathol; 2017 Feb; 37(1):55-60. PubMed ID: 28111041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting CTLA-4 in cancer: Is it the ideal companion for PD-1 blockade immunotherapy combinations?
    De Silva P; Aiello M; Gu-Trantien C; Migliori E; Willard-Gallo K; Solinas C
    Int J Cancer; 2021 Jul; 149(1):31-41. PubMed ID: 33252786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies.
    Salama AK; Moschos SJ
    Ann Oncol; 2017 Jan; 28(1):57-74. PubMed ID: 28177433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Immunotherapy of Renal Cell Carcinoma].
    Poprach A; Lakomý R; Büchler T
    Klin Onkol; 2017; 30(Supplementum3):55-61. PubMed ID: 29239194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
    Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
    Front Immunol; 2018; 9():1878. PubMed ID: 30158932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapy for esophageal squamous cell carcinoma: a review.
    Mimura K; Yamada L; Ujiie D; Hayase S; Tada T; Hanayama H; Thar Min AK; Shibata M; Momma T; Saze Z; Ohki S; Kono K
    Fukushima J Med Sci; 2018 Aug; 64(2):46-53. PubMed ID: 30058598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characteristics of Immune Checkpoint Inhibitors Trials Associated With Inclusion of Patients With HIV: A Systematic Review and Meta-analysis.
    Sorotsky H; Hogg D; Amir E; Araujo DV
    JAMA Netw Open; 2019 Nov; 2(11):e1914816. PubMed ID: 31702796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
    Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M
    J Immunother Cancer; 2016; 4():76. PubMed ID: 27895917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.